Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, programmed death-ligand 1 (PD-L1)-negative nonsquamous non-small cell lung cancer (NSCLC). In ...

-- STK-012 is an <ALPHA>/<BETA> biased IL-2 designed to specifically stimulate antigen activated T cells -- Results from an ongoing Phase 1a/1b to be presented at SITC -- Company will also present new ...

Allosite Therapeutics, a biotechnology company discovering and developing innovative integrin therapies for kidney diseases and other immunologic conditions, today announced that the company will ...

Patients with obesity and asthma who used GLP-1 receptor agonists had significantly fewer exacerbations and prednisone use ...

CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from ...

But to ensure the closest shave possible, while also avoiding irritation and ingrown hairs — not to mention painful nicks — ...

In a world that chases fitness and wellness amidst the hustle of daily lives, weight loss jabs have become the magic pills ...

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...

Electra Therapeutics has completed an oversubscribed $183 million Series C financing it said will fund a global pivotal trial of its lead pipeline candidate, a frontline treatment for secondary ...

The research conducted by Professor Zou Zui and his team focuses on the immunoregulatory mechanisms in sepsis. As a ...

NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, ...

BackgroundSepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It ...